Wang Zhiyi, Zhou P U, Li Guanghui
Institute for Cancer Research in People's Liberation Army, Xinqiao Hospital, Third Military Medical University, Chongqing 400037, P.R. China.
Oncol Lett. 2016 Jul;12(1):356-360. doi: 10.3892/ol.2016.4574. Epub 2016 May 16.
Treatment with epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) is the first-line strategy for patients with non-small cell lung cancer (NSCLC) harboring EGFR-activating mutations. Acquired resistance to EGFR-TKIs is inevitable in patients receiving EGFR-TKI therapy. Treatment with bevacizumab can induce a marked improvement in the overall and progression-free survival of patients with NSCLC; however, the effect of bevacizumab on TKI resistance in patients with NSCLC with an activating EGFR mutation is largely unknown. The present study reports the case of a patient with advanced, metastatic lung adenocarcinoma harboring 19 Del mutations, and who developed resistance to afatinib. The addition of bevacizumab to afatinib treatment was shown to overcome the acquired TKI resistance in the patient, as well as to promote an improved outcome for her brain metastases.
对于携带表皮生长因子受体（EGFR）激活突变的非小细胞肺癌（NSCLC）患者，使用表皮生长因子受体酪氨酸激酶抑制剂（EGFR-TKIs）进行治疗是一线治疗策略。接受EGFR-TKI治疗的患者不可避免地会出现对EGFR-TKIs的获得性耐药。使用贝伐单抗进行治疗可显著改善NSCLC患者的总生存期和无进展生存期；然而，贝伐单抗对具有EGFR激活突变的NSCLC患者的TKI耐药性的影响在很大程度上尚不清楚。本研究报告了1例携带19号外显子缺失（19 Del）突变的晚期转移性肺腺癌患者，该患者对阿法替尼产生了耐药。研究表明，在阿法替尼治疗中加用贝伐单抗可克服该患者获得性TKI耐药，同时改善其脑转移的预后。
